NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2022-05-11
Target enrollment:
Participant gender:
Summary
This is an open label, randomized phase 2 study of NaliCap (irinotecan liposome/Capecitabine)
compared to NAPOLI (irinotecan liposome/5-FU/LV) in gemcitabine-pretreated advanced
pancreatic cancer patients.